CGRP vs Neuromedin S — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide produced by alternative splicing of the calcitonin gene in neurons. It is the most abundant neuropeptide in the sensory nervous system, expressed in trigeminal ganglion neurons and released from perivascular n...
Calculate CGRP dose →Neuromedin S (NMS) is a 36-amino acid amidated neuropeptide discovered in 2005 that shares a C-terminal amino acid sequence with neuromedin U (NMU) and activates the same NMUR1 and NMUR2 receptors. However, NMS has a markedly different expression pattern: while NMU is broadly exp...
Calculate Neuromedin S dose →| Parameter | CGRP | Neuromedin S |
|---|---|---|
| Category | Neuropeptide | Neuropeptide |
| Research | FDA Approved (Anti-CGRP antibodies) | Research |
| Half-Life | ~7-10 min (plasma; native) | Short (minutes, estimated) |
| Typical Dose | Anti-CGRP mAbs: 70-240 mg SC monthly or quarterly | 1-10 nmol (central, animal) |
| Frequency | Monthly or quarterly (approved antibodies) | Variable |
| Route | Endogenous; IV/SC (research) | Intracerebroventricular, Subcutaneous |
| FDA Status | Anti-CGRP antibodies approved (erenumab, fremanezumab, galcanezumab, eptinezumab) | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.